Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Completion of SBIRT (specific aim 1) |
We will compare the proportion of participants that complete a screen for mental health and substance use, the proportion of those screening positive that are referred to treatment, and the proportion of those referred to treatment that had at least one mental health and/or substance use disorder treatment appointment among those assigned to LTW, compared to TAU. |
Screening through 3-months post study enrollment |
|
Primary |
Time to Treatment (specific aim 1) |
Time from completion of screening positive to time of first mental health or substance use treatment appointment (if a referral to treatment was appropriate) among those assigned to LTW, compared to TAU. |
Screening through 3-months post study enrollment |
|
Primary |
Change in Mental Health Symptoms (specific aim 1) |
Mean change in the Edinburgh Postnatal Depression Scale (EPDS) among women referred for treatment. A score of 10 or more on the Edinburgh Postnatal Depression Scale suggests clinically elevated depressive symptoms requiring further evaluation. |
Change from baseline EPDS at 3-months post study enrollment |
|
Primary |
Change in Substance Use (specific aim 1) |
Change in substance use frequency and amount as measured by the National Institute on Drug Abuse (NIDA)-Modified Assist among women referred for treatment. A score of 0-3 (0-4 for cannabis) has an indicated response for Brief Education, a score of 4-26 (5-26 for cannabis) has an indicated response for Brief Intervention and a score of 27+ has an indicated response for Brief Intervention (offer options that include treatment). |
Change from baseline substance use at 3-months post study enrollment |
|
Primary |
Change in Maternal Functioning (specific aim 1) |
Change in maternal functioning measured by the Medical Outcomes Study Short Form 36 (SF-36v2). |
Change from baseline maternal functioning at 3-months post study enrollment |
|
Primary |
Attendance to Treatment (specific aim 2) |
Treatment attendance (defined as attending at least 1 or more visits with a mental health and/or substance use disorder (SUD) treatment provider during pregnancy and the postpartum year) |
During pregnancy and the postpartum year |
|
Secondary |
Recruitment (specific aim 1) |
The proportion of patients who agree to participate as compared to the total number solicited to enroll for each recruitment approach |
24 months |
|
Secondary |
Attrition (specific aim 1) |
Proportion of study participants that prematurely terminate i.e., do not complete screenings, or are unable to be contacted for referral and/or treatment. |
Through study completion, an average of 3 months |
|
Secondary |
Study Retention (specific aim 1) |
Proportion of study participants that complete all assessment points associated with the protocol. |
Through study completion, an average of 3 months |
|
Secondary |
Treatment Attendance (specific aim 1) |
Proportion of participants that attended a mental health or substance use treatment appointment. |
Through study completion, an average of 3 months |
|
Secondary |
Change in Health-Related Social Needs (specific aim 1) |
Change in health-related social needs measured by the Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool among those assigned to LTW, compared to TAU |
Change from baseline Health-Related Social Needs use at 3-months post study enrollment |
|
Secondary |
Voice Biomarkers (specific aim 1) |
Voice analysis will be completed using an online platform SurveyLex (owned by NeuroLex, Inc.). Among women referred for treatment, we will analyze voice recordings for characteristics (acoustic, linguistic, or meta-feature) which may be compared between those assigned to LTW and those assigned to TAU |
Baseline through 3-months post study enrollment |
|
Secondary |
Change in Mental Health Symptoms-Depression (specific aim 2) |
Among women referred for treatment, we will compare the mean change in the Edinburgh Postnatal Depression Scale (EPDS) among those assigned to LTW, compared to TAU. A score of 10 or more on the Edinburgh Postnatal Depression Scale suggests clinically elevated depressive symptoms requiring further evaluation. A higher score on the EPDS is a worse outcome. |
Change from baseline mental health symptoms (depression) at 3-months post study enrollment |
|
Secondary |
Change in Mental Health Symptoms-Anxiety (specific aim 2) |
Among women referred for treatment, we will compare the mean change in the Generalized Anxiety Disorder-7 (GAD-7) among those assigned to LTW, compared to TAU. A score of 1-4 on the GAD-7 indicates minimal anxiety, 5-9 is mild anxiety, 10-14 is moderate anxiety and 15-21 is severe anxiety. A higher score on the GAD-7 is a worse outcome. |
Change from baseline mental health symptoms (anxiety) at 3-months post study enrollment |
|
Secondary |
Change in Mental Health Symptoms-Suicidal Ideation (specific aim 2) |
Among women referred for treatment, we will compare the mean change in the Columbia Suicide Severity Rating Scale (CSSRS) among those assigned to LTW, compared to TAU. There are no specified clinical cutoffs due to the binary nature of the responses to items. |
Change from baseline mental health symptoms (suicidal ideation) at 3-months post study enrollment |
|
Secondary |
Change in Substance Use-NIDA Modified Assist (specific aim 2) |
Among women referred for treatment, we will compare change in substance use frequency and amount as measured by the NIDA-Modified Assist among those assigned to LTW, compared to TAU. A score of 0-3 (0-4 for cannabis) has an indicated response for Brief Education, a score of 4-26 (5-26 for cannabis) has an indicated response for Brief Intervention and a score of 27+ has an indicated response for Brief Intervention (offer options that include treatment). |
Change from baseline substance use at 3-months post study enrollment |
|
Secondary |
Change in Substance Use-Timeline Follow Back (specific aim 2) |
Among women referred for treatment, we will compare change in substance use frequency and amount as measured by Timeline Follow-Back (TLFB) among those assigned to LTW, compared to TAU. |
Change from baseline substance use at 3-months post study enrollment |
|
Secondary |
Change in Maternal Functioning (specific aim 2) |
Among women referred for treatment, we will compare the change in maternal functioning measured by the Medical Outcomes Study Short Form 36 (SF-36v2) among those assigned to LTW, compared to TAU. |
Change from baseline maternal functioning at 3-months post study enrollment |
|
Secondary |
Change in Health-Related Social Needs |
Among women referred for treatment, we will compare the change in health-related social needs measured by the Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool among those assigned to LTW, compared to TAU. |
Change from baseline Health-Related Social Needs use at 3-months post study enrollment |
|